Skip to main content

Table 1 Grouping conditions and characteristics of subjects

From: Combined effect of branched-chain amino acids and taurine supplementation on delayed onset muscle soreness and muscle damage in high-intensity eccentric exercise

  Supply condition Physiological characteristics before experiment
Group BCAA Taurine Age (years) Height (cm) Body W. (kg) Fat (%) Muscle W. (kg) MVC (Nm) CIR (mm)
PLCB Placebo-1 Placebo-2 22.2 ± 1.1 170.8 ± 1.9 67.5 ± 3.5 18.3 ± 1.9 51.9 ± 1.8 36.5 ± 3.0 257.4 ± 7.6
BA 3.2 g Placebo-2 22.9 ± 1.1 176.7 ± 3.6 73.5 ± 4.3 20.1 ± 1.7 55.3 ± 2.4 41.9 ± 3.8 267.7 ± 7.9
TAU Placebo-1 2.0 g 22.2 ± 0.8 173.7 ± 2.2 65.5 ± 2.7 17.3 ± 1.3 51.7 ± 1.7 39.1 ± 2.4 251.3 ± 7.4
COMB 3.2 g 2.0 g 23.1 ± 1.3 174.5 ± 1.8 61.5 ± 1.6 14.2 ± 1.0 50.0 ± 1.3 35.0 ± 2.6 243.4 ± 6.6
  1. Footnote: Data are expressed as means ± S. E. Abbreviation: PLCB, double-placebo control group; BA, branched-chain amino acids and placebo-2 supplement group; TAU, taurine and placebo-1 supplement group; COMB, combined (taurine and BCAA) supplement group; Placebo-1 and 2, placebo of BCAA and taurine supplementation, respectively (3.2g or 2.0g starch mainly), Body W., body weight; Muscle W., muscle weight; MVC, maximal voluntary strength of isometric contraction; CIR, upper arm circumference.